Gilead Sciences (MEX:GILD) Interest Expense : MXN-19,540 Mil (TTM As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Gilead Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gilead Sciences's interest expense for the three months ended in Mar. 2025 was MXN -5,319 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-19,540 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gilead Sciences's Operating Income for the three months ended in Mar. 2025 was MXN 50,941 Mil. Gilead Sciences's Interest Expense for the three months ended in Mar. 2025 was MXN -5,319 Mil. Gilead Sciences's Interest Coverage for the quarter that ended in Mar. 2025 was 9.58. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gilead Sciences Interest Expense Historical Data

The historical data trend for Gilead Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Interest Expense Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-19,573.73

-20,534.51

-18,228.76

-16,023.69

-20,376.02

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-4,215.45	-4,341.86	-4,686.29	-5,193.07	-5,319.13

Gilead Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-19,540 Mil.

Gilead Sciences (MEX:GILD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gilead Sciences's Interest Expense for the three months ended in Mar. 2025 was MXN-5,319 Mil. Its Operating Income for the three months ended in Mar. 2025 was MXN50,941 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was MXN0 Mil.

Gilead Sciences's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2025 )	/	Interest Expense (Q: Mar. 2025 )
	=	-1	*	50940.918	/	-5319.132
	=	9.58

The higher the ratio, the stronger the company's financial strength is.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MEX:GILD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).